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Background
CD8-mediated virus inhibition can be detected in HIV-1+
subjects controlling virus replication in the absence of
ART. Characterizing the CD8+ T cells that mediate virus
inhibition is important for determining the nature of
CD8+ T cells that need to be elicited by an HIV-1 vaccine.
Methods
We used a 3-day CD8+ T cell mediated virus inhibition
assay (CD8 VIA) to assess CD8+ function. Primary CD4+
enriched lymphocytes were infected with reporter viruses
expressing transmitted/founder envelopes in the presence
of serial dilutions of autologous CD8+ T cells. We exam-
ined activated CD8+ T cells from 22 HIV-1+ subjects (of
which 15 were virus controllers (VC)), 37 HIV-1 vaccinees
(DNA prime, rAd5 boost encoding HIV-1 Env and Gag-
Pol) and 6 seronegative donors. Phenotypic analysis of
HIV-1 specific CD8+ cells was determined by 13 color flow
cytometry. Phenotypically-defined CD8+  T cell subsets
from selected donors were sorted by flow cytometry and
tested for virus suppression.
Results
VCs had robust antiviral activity against both transmitted/
founder and NL4-3 enveloped viruses (1.43 +/- 0.67 log
reduction). Among vaccinees, CD8 VIA correlated with
HIV-1 specific CD107a expression; and weakly with IFN-
gamma expression. No correlations were observed with
CD8+ cell expression of IL-2, TNF-alpha, or MIP-1 beta.
Virus inhibition by sorted cells was absent from naive
CD8+ T cells; the predominant activity was from central
and early effector memory populations.
Conclusion
CD8-mediated virus inhibition, as measured in a 3-day
assay with early transmitted reporter viruses, was present
in HIV-1+ subjects and vaccinees. Among HIV-1+ subjects,
the activity was most robust in virus controllers. Virus sup-
pression correlates most strongly with CD107a, and may
come primarily from central memory populations. These
data provide insight into the mechanisms of viral inhibi-
tion, and suggest that functional analyses of CD8+ T cell
mediated virus inhibition could identify benchmarks for
successful T-cell directed vaccine strategies.
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